US Drug Companies Conducting More Clinical Trials Overseas To Reduce Costs, Speed Approval
Main Category: Pharma Industry / Biotech IndustryArticle Date: 18 May 2005 - 9:00 PDT
| Patient / Public: | ![]() |
3.5 (2 votes) |
| Healthcare Prof: | ![]() |
2 (2 votes) |
The pharmaceutical industry is conducting more clinical trials outside of the United States in part to lower costs, expedite approval and test drugs in countries where they will be sold,... USA Today reports. About 21% of drug industry spending for human drug testing was outside of the United States in 2004, up from 18% in 2000. Drug companies indicate that the number of U.S.-based clinical trials is not declining as "much as foreign ones are increasing," USA Today reports. Companies can reduce human testing costs by 10% to 50% by conducting trials in Eastern Europe, Asia, and Central and South America, Ronald Krall, GlaxoSmithKline head of development, said. Clinical and hospital costs are lower outside of the United States, and patient recruitment is less time consuming. In addition, Henry Gabelnick of Conrad, a reproductive health agency, said that companies are basing clinical trials in countries where there is greater incidence of some diseases. For example, Conrad next month will begin testing a vaginal gel to prevent transmission of HIV/AIDS in four African countries and India, where infection rates are higher. Fred Fiedorek, vice president of clinical research at Bristol-Myers Squibb, said more clinical trials are being conducted abroad in part because some nations, such as Japan, request that drugs are tested on their own populations before they are approved for use. In addition, international standards for administering clinical trials have been more widely adopted (Schmit, USA Today, 5/17).
"Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/24634.php>
APA
http://www.medicalnewstoday.com/releases/24634.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




